Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome
暂无分享,去创建一个
A. Cuneo | M. Krampera | D. Cilloni | C. Bosi | F. Heidel | F. Pane | M. Miglino | N. Vianelli | G. Caocci | M. Breccia | M. Cavo | M. Tiribelli | M. Bonifacio | A. Iurlo | B. Martino | G. Palumbo | N. Pugliese | G. Semenzato | M. Trawinska | E. Abruzzese | G. Benevolo | M. Bocchia | F. Cavazzini | R. Lemoli | G. Binotto | L. Scaffidi | D. Cattaneo | M. Crugnola | F. Palandri | E. Elli | A. Isidori | A. Tieghi | E. Beggiato | N. Polverelli | G. Auteri | D. Bartoletti | Simona Paglia | C. Mazzoni | Mattia Biondo | Marta Venturi
[1] P. Guglielmelli,et al. Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis , 2022, Blood Cancer Journal.
[2] J. Mascarenhas,et al. Thrombocytopenia in Patients With Myelofibrosis: A Practical Management Guide. , 2022, Clinical lymphoma, myeloma & leukemia.
[3] S. Verstovsek,et al. Momelotinib reduces transfusion requirements in patients with myelofibrosis , 2022, Leukemia & lymphoma.
[4] S. Verstovsek,et al. P1037: DOES EARLY INTERVENTION IN MYELOFIBROSIS IMPACT OUTCOMES? A POOLED ANALYSIS OF THE COMFORT I AND II STUDIES , 2021, HemaSphere.
[5] S. Verstovsek,et al. Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval , 2021, Annals of Hematology.
[6] S. Verstovsek,et al. Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia , 2021, Haematologica.
[7] F. Mannelli,et al. Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study , 2021, Leukemia.
[8] Kaori Ito,et al. Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis. , 2020, Blood advances.
[9] Angela G. Fleischman,et al. ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. , 2020, Blood advances.
[10] R. Greil,et al. Real‐world non‐interventional long‐term post‐authorisation safety study of ruxolitinib in myelofibrosis , 2020, British journal of haematology.
[11] R. Mesa,et al. Fedratinib in myelofibrosis. , 2020, Blood advances.
[12] S. Verstovsek,et al. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure , 2020, American journal of hematology.
[13] S. Verstovsek,et al. The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication. , 2020, Clinical lymphoma, myeloma & leukemia.
[14] R. Mesa,et al. Severe thrombocytopenia in myelofibrosis is more prevalent than previously reported. , 2020, Leukemia research.
[15] P. Guglielmelli,et al. Mutation‐enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera , 2020, British journal of haematology.
[16] R. Foà,et al. Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis , 2019, Cancer.
[17] R. Latagliata,et al. Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. , 2018, Leukemia research.
[18] S. Verstovsek,et al. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial , 2018, JAMA oncology.
[19] M. Ramírez,et al. Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia , 2018, British journal of haematology.
[20] H. Kantarjian,et al. Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis , 2018, European journal of haematology.
[21] Francisco Cervantes,et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses , 2017, Journal of Hematology & Oncology.
[22] Z. Shun,et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. , 2017, The Lancet. Haematology.
[23] R. Fanin,et al. Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis , 2017, Oncotarget.
[24] R. Fanin,et al. Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis , 2017, Oncotarget.
[25] J. Dipersio,et al. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial , 2017, Journal of Hematology & Oncology.
[26] T Giorgino,et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis , 2017, Leukemia.
[27] Mario Cazzola,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.
[28] Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405. , 2016, Blood.
[29] J. Cortes,et al. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. , 2015, JAMA oncology.
[30] M. Cazzola,et al. Mutations and prognosis in primary myelofibrosis , 2013, Leukemia.
[31] Francisco Cervantes,et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. , 2013, Blood.
[32] M. Griesshammer,et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Jason Gotlib,et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. , 2012, The New England journal of medicine.
[34] Francisco Cervantes,et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. , 2012, The New England journal of medicine.
[35] F. Passamonti,et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] M. Cazzola,et al. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. , 2010, Blood.
[37] Ayalew Tefferi,et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. , 2010, The New England journal of medicine.
[38] H. Kantarjian,et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. , 2010, Blood.
[39] D. Dingli,et al. Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. , 2007, Leukemia research.
[40] P. Campbell,et al. The myeloproliferative disorders. , 2006, The New England journal of medicine.
[41] R. Mesa,et al. Prognosis in transplant‐eligible patients with agnogenic myeloid metaplasia , 2006, Cancer.